单克隆球蛋白病的评估

Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.

• 摘要

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.

• 摘要

Katzmann JA, Dispenzieri A. Screening algorithms for monoclonal gammopathies. Clin Chem. 2008;54:1753-1755.

• 全文
• 摘要

Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.

• 全文
• 摘要

Kyle RA, Durie BG, Rajkumar SV, et al; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121-1127.

• 摘要

Dispenzieri A, Kyle R, Merlini G, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-224.

• 摘要

1.  Rajkumar SV, Dispenzieri A, Kyle RA. Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. Mayo Clin Proc. 2006;81:693-703.

• 摘要

2.  Kyle RA. Current concepts on monoclonal gammopathies. Aust N Z J Med. 1992;22:291-302.

• 摘要

3.  Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354:1362-1369.

• 全文
• 摘要

4.  International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.

• 摘要

5.  Fairfax KA, Kallies A, Nutt SL, et al. Plasma cell development: from B-cell subsets to long-term survival niches. Semin Immunol. 2008;20:49-58.

• 摘要

6.  McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol. 2005;23:487-513.

• 摘要

7.  Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006;6:741-750.

• 摘要

8.  Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5:230-242.

• 摘要

9.  Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116:5126-5129.

• 全文
• 摘要

10.  Katzmann JA, Kyle R. Immunochemical characterization of immunoglobulins in serum, urine, and cerebrospinal fluid. In: Detrick B, ed. Manual of molecular and clinical laboratory immunology. 7th ed. Washington, DC: American Society for Microbiology Press; 2006:88-100.

11.  Katzmann JA, Dispenzieri A. Screening algorithms for monoclonal gammopathies. Clin Chem. 2008;54:1753-1755.

• 全文
• 摘要

12.  O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254-263.

• 全文
• 摘要

13.  Witzig TE, Kimlinger TK, Ahmann GJ, et al. Detection of myeloma cells in the peripheral blood by flow cytometry. Cytometry. 1996;26:113-120.

• 摘要

14.  Albarracin F, Fonseca R. Plasma cell leukemia. Blood Rev. 2011;25:107-112.

• 摘要

15.  Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121:482-488.

• 全文
• 摘要

16.  Paiva B, Vidriales MB, Cervero J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112:4017-4023.

• 全文
• 摘要

17.  Rawstron AC, Orfao A, Beksac M, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica. 2008;93:431-438.

• 全文
• 摘要

18.  Axelsson U, Hallen J. Review of fifty-four subjects with monoclonal gammopathy. Br J Haematol. 1968;15:417-420.

• 摘要

19.  Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.

• 全文
• 摘要

20.  Saleun JP, Vicariot M, Deroff P, et al. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35:63-68.

• 全文
• 摘要

21.  Kyle RA, Durie BG, Rajkumar SV, et al; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24:1121-1127.

• 摘要

22.  Wadhera RK, Rajkumar SV. Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. Mayo Clin Proc. 2010;85:933-942.

• 摘要

23.  Wadhera RK, Kyle RA, Larson DR, et al. Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood. 2011;118:2985-2987.

• 全文
• 摘要

24.  Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc. 2007;82:1468-1473.

• 摘要

25.  Vachon CM, Kyle RA, Therneau TM, et al. Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood. 2009;114:785-790.

• 摘要

26.  Neriishi K, Nakashima E, Suzuki G. Monoclonal gammopathy of undetermined significance in atomic bomb survivors: incidence and transformation to multiple myeloma. Br J Haematol. 2003;121:405-410.

• 摘要

27.  Sonoda T, Nagata Y, Mori M, et al. Meta-analysis of multiple myeloma and benzene exposure. J Epidemiol. 2001;11:249-254.

• 摘要

28.  Baris D, Silverman DT, Brown LM, et al. Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health. 2004;30:215-222.

• 摘要

29.  Cuzick J, De Stavola B. Multiple myeloma: a case-control study. Br J Cancer. 1988;57:516-520.

• 全文
• 摘要

30.  Berenson JR, Vescio RA. HHV-8 and multiple myeloma. Pathol Biol (Paris). 1999;47:115-118.

• 摘要

31.  Fonseca R, Bailey RJ, Ahmann GJ, et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood. 2002;100:1417-1424.

• 全文
• 摘要

32.  Avet-Loiseau H, Facon T, Daviet A, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res. 1999;59:4546-4550.

• 全文
• 摘要

33.  Stewart AK, Fonseca R. Review of molecular diagnostics in multiple myeloma. Expert Rev Mol Diagn. 2007;7:453-459.

• 摘要

34.  Fonseca R, Debes-Marun CS, Picken EB, et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102:2562-2567.

• 全文
• 摘要

35.  Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467-472.

• 全文
• 摘要

36.  Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.

• 摘要

37.  Blade J, Fernandez-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-1893.

• 全文
• 摘要

38.  Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010;28:4976-4984.

• 摘要

39.  Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. Leuk Lymphoma. 2007;48:337-341.

• 摘要

40.  Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med. 2011;364:2365-2366.

• 全文
• 摘要

41.  Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med. 2005;143:777-784 (erratum in: Ann Intern Med. 2007;146:471).

• 摘要

42.  Cserti C, Haspel R, Stowell C, et al. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion. 2007;47:511-514.

• 摘要

43.  Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int. 2008;73:1282-1288.

• 摘要

44.  Sethi S, Zand L, Leung N,et al. Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol. 2010;5:770-782.

• 摘要

45.  Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-2472.

• 摘要

46.  Ansell SM, Kyle RA, Reeder CB, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85:824-833.

• 摘要

47.  Gertz MA, Kyle RA. Hyperviscosity syndrome. J Intensive Care Med. 1995;10:128-141.

• 摘要

48.  Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77:181-187.

• 摘要

49.  Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis. 2006;47:947-955.

• 摘要

50.  Kristinsson SY, Fears TR, Gridley G, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112:3582-3586.

• 摘要

51.  Dispenzieri A, Stewart AK, Chanan-Khan A, et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood. 2013;122:4172-4181.

• 全文
• 摘要

52.  Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-548.

• 摘要

53.  Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582-2590.

• 全文
• 摘要

54.  Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375:1721-1728.

• 摘要

55.  Hadden RDM, Nobile-Orazio E, Sommer C, et al. Paraproteinaemic demyelinating neuropathies. In: Gilhus NE, Barnes MP, Brainin M, eds. European handbook of neurological management. 2nd ed. Vol. 1. Oxford: Blackwell Publishing; 2011:351-361.

• 全文

56.  Bird J, Behrens J, Westin J, et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology, UK Myeloma Forum and Nordic Myeloma Study Group. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147:22-42 (erratum in: Br J Haematol. 2010;148:491).

• 全文
• 摘要

57.  Katzmann JA, Dispenzieri A, Kyle RA, et al. Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays. Mayo Clin Proc. 2006;81:1575-1578.

• 摘要

58.  Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48:1437-1444.

• 全文
• 摘要

59.  Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev. 2007;21:255-265.

• 摘要

60.  Sinclair D, Ballantyne F, Shanley S, et al. Estimation of paraproteins by immunoturbidimetry and electrophoresis followed by scanning densitometry. Ann Clin Biochem. 1990;27:335-337.

• 摘要

61.  Katzmann JA, Clark R, Wiegert E, et al. Identification of monoclonal proteins in serum: a quantitative comparison of acetate, agarose gel, and capillary electrophoresis. Electrophoresis. 1997;18:1775-1780.

• 摘要

62.  Bradwell AR, Carr-Smith HD, Mead GP, et al. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361:489-491.

• 摘要

63.  Dispenzieri A, Kyle R, Merlini G, et al; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23:215-224.

• 摘要

64.  Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812-817.

• 全文
• 摘要

65.  Hughes M, Soutar R, Lucraft H, et al; UKMF Guidelines Working Group. British Committee for Standards in Haematology. Guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas: 2009 update. http://www.bcshguidelines.com (last accessed 24 November 2016).

• 全文

66.  Chee CE, Dispenzieri A, Gertz MA. Amyloidosis and POEMS syndrome. Expert Opin Pharmacother. 2010;11:1501-1514.

• 全文
• 摘要